Study design Origin of
patients
TB-IRIS
group
N
Control group
(non-IRIS)
N
Time between HAART onset and IRIS
(days
)
CD4+ T-lymphocyte
(at pre-HAART) (cell/mm
3)
CD4+ T-lymphocyte
(at IRIS)
(cell/ mm
3)
References
Case report England 1 2 35 150 294 [37]
Prospective Sub-Saharan Africa* 7 (pIRIS) 12 23 32 107 [18]
Prospective Malaysia† 3 (pIRIS) 8 Patient 1: 21 NI NI [30]
Patient 2: 84
Patient 3: 98
Prospective Sub-Saharan Africa* 11 (pIRIS) 13 23 26 86 [21]
Cross-sectional South Africa 35 (pIRIS) 19 14 51 181 [20]
Prospective 10 (pIRIS) 41 15 195 NI
Prospective Sub-Saharan Africa* 11 (pIRIS) 13 26 37 108 [22]
Prospective Cambodia§ 15 (pIRIS) 55 10 45 NR [31]
11 (uIRIS) 206 10
Prospective Thailand 22 (pIRIS) 104 14 35 144 [32]
Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [33]
Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [19]
Case report Thailand 1 (uIRIS) 4 60 46 155 [34]
Case report South Africa 22 (pIRIS) 22 14 NI NI [23]
Prospective Malaysia† 3 (pIRIS) 9 49 15 147 [35]
Case-control South Africa 18 (uIRIS) 58 (HIV) 55 115 154 [24]
51 (HIV-TB)
Prospective South Africa 1 (uIRIS) NI 28 4 41 [25]
5(pIRIS) 42
Prospective South Africa 8 (TB-MDR) 25 (TB-FS) 14 50 NI [26]
3 (TB-RM) 55
Prospective Cambodia§ 15 (pIRIS) 30 10 45 NI [36]
Prospective South Africa 16 18 14 93 158 [27]
Prospective Gambia 20 (pIRIS) 16 21 60 180 [28]
Prospective Uganda 18 (pIRIS) 18 14 19 NI [29]
pIRIS: tuberculosis associated with paradoxical IRIS; uIRIS: tuberculosis associated with unmasking IRIS; NI: Not Informed; TB-MDR: Tuberculosis Multi-Drug Resistant; TB-RM: Tuberculosis Mono-Resistant to Rifampicin; TB-FS: Tuberculosis Full Sensitive;*, †, §patients evaluated in the same studies.
Table 1: Characteristics of included studies.